Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma

A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.

Disease Types: Melanoma

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A phase 3 study of fixed dose combinations of fianlimab and cemiplimab versus relatlimab and nivolumab in participants with unresectable or metastatic melanoma.

For More Information:

https://clinicaltrials.gov/study/NCT06246916?term=R3767-ONC-22122&rank=1#more-information